loader image
Monday, December 22, 2025
85.1 F
McAllen
- Advertisement -

LEARN MORE ABOUT DR. BILAL BIN HAFEEZ

Community NewsNews
1293

Translate to Spanish or other 102 languages!

Graduate research assistants Emmanuel Anning, Godwin Peasah-Darkwah and Asif Shahriar work in the lab to assist in the development of a treatment for advanced pancreatic cancer. (UTRGV Image Office of Research & New Program Development)

Mega Doctor News

- Advertisement -

Hafeez is the founding member of the first nationally recognized South Texas Center of Excellence in Cancer Immunology at the UTRGV School of Medicine and is an accomplished researcher with a background in immunopharmacology, cancer therapeutics and cancer biology. Hafeez, a Nehtaur, Bijnor, Uttar Pradesh, India native, has earned prestigious grant awards and is an active member of the American Association for Cancer Research and the Indian Association for Cancer Research. His significant contributions to cancer biology and molecular therapeutics have led to his numerous published manuscripts in scientific journals. 

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
School of Medicine earns $1.45M grant for pancreatic cancer research
Next article
Nursing and Allied Health to host new conference dedicated to health careers for students

More Articles

STHS’ “South Texas Healthy Living” Dedicates Episode to Colon Health, Dec. 28th

It may come as a surprise, but colon health is a vital part of your overall well-being; it profoundly impacts nearly every system in the body.

6 Depression Symptoms in Midlife Linked to Almost 50% Higher Dementia Risk

In 2021, about 57 million people globally were living with dementia — an umbrella term for neurological conditions that impact a person’s cognitive skills and memory, such as Alzheimer’s disease and vascular dementia

From Patient to Hero: Isaac Garza Delivers 2,089 Smiles This Holiday Season

Mega Doctor News For Isaac Garza, it’s better to give than to receive during the...

FDA Approves Daily Pill to Treat Low Libido in Women After Menopause

On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65.
- Advertisement -

We feature articles about leading professionals in the medical and healthcare industry in the South Texas area. We are your connection to the medical community!

Pick up a copy of our publication on more than 800 locations Valley-wide.

Contact Us

Office (956) 928-1255

Sales (956) 451-4585

info@tbbmega.com

sales@tbbmega.com

Subscribe

© Mega Doctor News 2025

×